Meta-Analysis
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2014; 20(40): 14973-14985
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14973
Standard triple therapy for Helicobacter pylori infection in China: A meta-analysis
Ben Wang, Zhi-Fa Lv, You-Hua Wang, Hui Wang, Xiao-Qun Liu, Yong Xie, Xiao-Jiang Zhou
Ben Wang, Zhi-Fa Lv, You-Hua Wang, Hui Wang, Xiao-Qun Liu, Yong Xie, Xiao-Jiang Zhou, Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang 330000, Jiangxi Province, China
Author contributions: Wang B and Lv ZF contributed equally to this work; Wang B and Lv ZF designed the study, analyzed the data and wrote the manuscript; Wang B, Lv ZF and Wang YH designed the research; Wang B, Lv ZF, Wang YH, Wang H and Liu XQ performed the research; Xie Y and Zhou XJ designed the study and edited the manuscript as corresponding author.
Supported by National Science and Technology Major Projects for “Major New Drugs Innovation and Development” of China, No. 2011ZX09302-007-03
Correspondence to: Yong Xie, MD, PhD, Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, No. 17 Yongzhengwai Street, Donghu District, Nanchang 330000, Jiangxi Province, China. xieyong_med@163.com
Telephone: +86-791-88692507 Fax: +86-791-88623153
Received: February 28, 2014
Revised: May 8, 2014
Accepted: May 25, 2014
Published online: October 28, 2014
Core Tip

Core tip: This study compared the efficiency of standard triple therapy with other pre-existing and new therapies on the Chinese mainland and examined the eradication rates for Helicobacter pylori in China. The results showed that the standard triple therapy including proton pump inhibitors, amoxicillin and clarithromycin might not be suitable for first-line therapy.